冠状动脉介入术后应用阿托伐他汀治疗对高敏C反应蛋白的影响

Effect of atorvastatin on high-sensitivity C-reactive protein of the patients underwent percutaneous coronary intervention

目的研究冠状动脉介入术后应用阿托伐他汀治疗对高敏C反应蛋白(hs-CRP)的影响。方法按照随机数字表法将我院2012年2月至2014年11月收治的235例冠状动脉介入术患者分为观察组(118例)和对照组(117例)。所有患者均进行常规治疗,观察组患者在此基础上采取阿托伐他汀治疗。记录两组患者在冠状动脉介入术前和术后1、2、4周的血清hs-CRP水平,术前和术后4周的MCP-1、s Fas水平,比较肝功能变化,观察不良反应。结果术后1、2、4周,观察组患者的hs-CRP水平低于对照组,差异有统计学意义(P<0.05);术后4周,观察组患者的MCP-1和s Fas水平[(245.5±75.7)、(173.4±35.6)ng/L]显著低于对照组[(674.2±67.2)、(367.6±89.4)ng/L],差异有统计学意义(P<0.05);术后4周,观察组患者BUN、Cr、Ccr、Cys C、GFR指标的改善程度优于对照组,差异有统计学意义(P<0.05);观察组总不良反应发生率(15.25%)显著低于对照组(22.03%),差异有统计学意义(P<0.05)。结论冠状动脉介入术后应用阿托伐他汀治疗,能够明显降低hsCRP、M CP-1及s Fas的水平,防止再狭窄的发生,值得推广应用。

Objective To study the effect of atorvastatin on high-sensitivity C-reactive protein（ hs-CRP） of the patients underwent percutaneous coronary intervention. Methods Two hundred and thirty-five cases of percutaneous coronary intervention in our hospital fromFebruary 2012 to November 2014 were divided into observation group（ n = 118） and control group（ n = 117） according to a randomnumber table method. All the patients underwent conventional treatment,and the observation group was added with atorvastatin. The serumhs-CRP was detected before and at 1,2,4 weeks after percutaneous coronary intervention,and the MCP-1 and s Fas changes were recorded before and at4 weeks after operation,the liver function and adverse reactions were observed. Results At 1,2,4 weeks after percuta-neous coronary intervention,the hs-CRP levels in observation group were lower than those of control group（ P〈0. 05）. The levels of MCP-1 and s Fas were lower than those of control group after 4 weeks：（ 245. 5 ± 75. 7） ng /L vs.（ 674. 2 ± 67. 2） ng / L,（ 173. 4 ± 35. 6） ng / L vs.（ 367. 6 ± 89. 4） ng / L,P〈0. 05. The BUN,Cr,Ccr,Cys C,GFR in observation group were improved more significantly than those of control group（ P〈0. 05）. The total incidence of adverse reactions in observation group（ 15. 25%） was lower than that of control group（ 22. 03%）,there was significant difference between the two groups（ P〈0. 05）. Conclusion Atorvastatin can significantly reduce the hs-CRP,MCP-1 and s Fas levels of patients with postoperative coronary intervention,prevent the restenosis,it is worthy of widely use.